Innovent Biologics, Inc. (HKG: 1801)
Hong Kong
· Delayed Price · Currency is HKD 37.20
-0.50 (-1.33%)
Nov 15, 2024, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 4,872 employees as of December 31, 2023. The number of employees decreased by 422 or -7.97% compared to the previous year.
Employees
4,872
Change (1Y)
-422
Growth (1Y)
-7.97%
Revenue / Employee
1.52M HKD
Profits / Employee
-261.61K HKD
Market Cap
60.93B
Employees Chart
Innovent Biologics News
- 12 days ago - Innovent Biologics (1801) Terminates Share Subscription Deal with Lostrancos - GuruFocus
- 18 days ago - Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics - PRNewsWire
- 4 weeks ago - Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint - PRNewsWire
- 5 weeks ago - Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
- 7 weeks ago - Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis - PRNewsWire
- 2 months ago - Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress - PRNewsWire
- 2 months ago - Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress - PRNewsWire
- 2 months ago - Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 - PRNewsWire